Aspire Biopharma Holdings (ASBP) Other Non-Current Assets (2022)
Aspire Biopharma Holdings (ASBP) posted quarterly Other Non-Current Assets of $80170.0 for Q4 2022, down 65.27% quarter-over-quarter from $230848.0 in Q3 2022.
Aspire Biopharma Holdings (ASBP) Other Non-Current Assets (2022) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Other Non-Current Assets for 1 consecutive years, with $80170.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Other Non-Current Assets changed N/A year-over-year to $80170.0; the TTM figure through Dec 2022 stood at $80170.0 (changed N/A YoY), while the FY2022 annual figure was $80170.0, changed N/A from the prior year.
- Other Non-Current Assets declined to $80170.0 in Q4 2022 per ASBP's latest filing, from $230848.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $530459.0 in Q1 2022 and bottomed at $80170.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 80,170.00 |
| Sep 30, 2022 | 230,848.00 |
| Jun 30, 2022 | 381,472.00 |
| Mar 31, 2022 | 530,459.00 |